Fluconazole therapy of oropharyngeal candidiasis in a patient with multiple endocrine failure does not correlate with Candida albicans susceptibility to fluconazole in vitro

Journal of Medical and Veterinary Mycology

Volumn 34, Issue 3, 1996, Pages 205-208

  Field, E A ^a   Millns, B ^a   Pearce, P K ^a   Martin, M V ^a   Parkinson, T ^b   Hitchcock, C A ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Azole resistance; Candidiasis; Endocrinopathy; Fluconazole; Oropharyngeal; RFLP

Indexed keywords

FLUCONAZOLE; KETOCONAZOLE; MICONAZOLE;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; DRUG EFFICACY; DRUG SENSITIVITY; ENDOCRINE DISEASE; ESOPHAGUS; GOOD CLINICAL PRACTICE; HUMAN; IN VITRO STUDY; MALE; ORAL DRUG ADMINISTRATION; OROPHARYNX; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 80051496795     PISSN: 02681218     EISSN: None     Source Type: Journal    
DOI: 10.1080/02681219680000341     Document Type: Article

References (26)

1. Odds FC. Candida and Candidosis, 2nd edn. London: Baillière Tindall, 1988.
2. Banerjee SN, Emori TG, Culver DH, et al. & the National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary blood stream infections in the United States, 1980-89. Am J Med 1991; 91 (Suppl. 3B): 86S-89S.
3. British Society for Antimicrobial Chemotherapy Working Party. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemother 1993; 32: 5-21.
4. Just-Nubling C, Gentschew G, Meissner K, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991; 10: 917-21.
5. Marriott DJ, Jones PD, Joy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Austr 1993; 158: 312-16.
6. Rex JH, Pfaller MA, Barry AL, et al. & the NIAID Mycoses Study Group & the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-4.
7. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl. 3): S318-S326.
8. Koks CHW, Schepens MHJ, Burger DM, et al. Drug development report (9): fluconazole in the treatment and prophylaxis of oral candidosis in HIV-injected patients. J Drug Devel 1993; 5: 235-49.
9. Ng TTC, Denning DW. Fluconazole resistance in Candida patients with AIDS: a therapeutic approach. J Infect 1993; 26: 117-25.
10. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994; 18: 240-2.
11. Ruhnke M, Eigler A, Engelmann E, Geiseler B, Trautmann M. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 1994; 22: 132-6.
12. Ruhnke M, Eigler A, Tennagen I, et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis in human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-8.
13. Sanguineti A, Carmichael JK, Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993; 153: 1122-4.
14. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993; 12: 911-15.
15. Vuffray A, Durussel C, Boerlin-Petzold P, et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994; 8: 708-9.
16. Horsburgh, CR, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983; 74 (Suppl. 1B): 23-9.
17. Smith KJ, Warnock DW, Kennedy CTC, et al. Azole resistance in Candida albicans. J Med Vet Mycol 1986; 24: 133-44.
18. Warnock DW, Johnson EM, Richardson MD, Vickers CFH. Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet 1983; i: 642-3.
19. Porter SR, Scully C. Candidiasis endocrinopathy syndrome. Oral Surg Oral Med Oral Pathol 1986; 61: 573-8.
20. Pfaller MA, Rinaldi MG, Galgiani JN, et al. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother 1990; 34: 1648-54.
21. Smith R A, Hitchcock CA, Evans EGV, Lacey CJN, Adams DJ. The identification of Candida albicans strains by restriction fragment length polymorphism analysis of DNA. J Med Vet Mycol 1989; 27: 431-4.
22. De Wit S, Clumeck N. Therapeutic approach to mycotic infections in AIDS patients. Rev Med Microbiol 1991; 2: 57-60.
23. Grant SM, Clissold SP. Fluconazole: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916.
24. Hitchcock CA. Cytochrome P-450-dependent 14a-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem Soc Trans 1991; 19: 782-7.
25. Sheehan DJ, Espinel-Ingroff A, Moore LS, Webb CD. Antifungal susceptibility testing of yeasts: a brief overview. Clin Infect Dis 1993; 17 (Suppl. 2): S494-500.
26. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts: proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, PA, 1992.